Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Femasys Inc(FEMY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for FEMY
09/23/2026: FEMY (1-star) is currently NOT-A-BUY. Pass it for now.
Femasys Inc is a medical technology company developing non-surgical, office-based solutions for women's reproductive health. The company is characterized by a proprietary, innovative pipeline that aims to reduce medical costs and improve patient experience. While Femasys holds a specialized position in a growing niche, it remains an early-stage company that is not currently profitable. Primary risks involve navigating regulatory hurdles, competing with large, well-resourced medical device manufacturers, and achieving physician adoption. The stock may suit growth-oriented investors with a high risk tolerance who are looking for exposure to reproductive health innovation, provided they monitor clinical and regulatory developments closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential linked to pipeline success but carries the risks typical of early-stage medical technology firms. |
| Momentum investor | Mixed fit | Momentum interest is typically tied to positive clinical data releases or regulatory milestones rather than current fundamentals. |
| Value investor | Weak fit | The company is not currently profitable, making traditional value metrics like P/E ratios inapplicable. |
| Dividend investor | Weak fit | Femasys does not pay a dividend and is focused on capital preservation and growth. |
| Low-risk investor | Weak fit | The inherent uncertainty in clinical development and regulatory approval makes this an unsuitable investment for risk-averse individuals. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap biotechnology and medical device stocks often experience sharp price swings based on clinical or regulatory news. |
| Valuation risk | Medium / high | Valuation is highly speculative, relying on future revenue potential rather than existing earnings. |
| Competition risk (Large medical device firms) | High | Established players like Hologic have greater resources for marketing and distribution. |
| Business quality | Medium | The company is still proving its commercial model, though it holds unique, proprietary technology. |
| Dividend income | Low / none | Investors should not expect any income from dividends. |
| Execution risk | High | Success depends on effectively navigating FDA pathways and achieving physician adoption. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 31.09% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 21.44M USD | Price to earnings Ratio - | 1Y Target Price 14.33 |
Price to earnings Ratio - | 1Y Target Price 14.33 | ||
Volume (30-day avg) 1.4M shares | Beta -2.07 | 52 Weeks Range 2.02 - 22.20 | Updated Date 09/23/2026 |
52 Weeks Range 2.02 - 22.20 | Updated Date 09/23/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.73 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales | Revenue generated from the sale of diagnostic and therapeutic devices to healthcare providers. | The company makes money by selling specialized medical devices to doctors for use in women's health clinics. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 24.54M | Price to Sales(TTM) 9.32 |
Enterprise Value 24.54M | Price to Sales(TTM) 9.32 | ||
Enterprise Value to Revenue 10.74 | Enterprise Value to EBITDA 0.24 | Shares Outstanding 8.38M | Shares Floating 7.35M |
Shares Outstanding 8.38M | Shares Floating 7.35M | ||
Percent Insiders 3.92 | Percent Institutions 47.26 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Femasys Inc
Exchange NASDAQ | Headquarters Suwanee, GA, United States | ||
IPO Launch date 2021-06-18 | Founder, President, CEO & Director Ms. Kathy Lee-Sepsick M.B.A. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 51 | Website https://femasys.com |
Full time employees 51 | Website https://femasys.com | ||
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.